Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pardes Biosciences gets patent related to SARS-CoV-2 antiviral

Pfizer and Merck are also developing antivirals targeting the novel coronavirus.

By Brian Buntz | September 21, 2021

Pardes BiosciencesPardes Biosciences, a biopharma upstart based in Carlsbad, California, has announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497. The patent relates to compounds intended to inhibit the main protease (Mpro) of SARS-CoV-2.  

“This issued patent is the first from our growing IP portfolio and reflects our commitment to discovering and developing novel therapies for important unmet medical needs,” said Uri Lopatin, the company’s CEO, in a statement. 

The company filed its first patent applications in April 2020. Pardes was founded in late February.  

Last month, the company announced that it had launched a first-in-human trial for its SARS-CoV-2 antiviral. 

Oral antivirals offer promise in battling the pandemic in the long term in terms of reducing the severity of COVID-19 infections and potentially reducing transmission. 

“This goes back to breaking the [viral] replication machinery,” said Lopatin. If people infected with SARS-CoV-2 “are not making as much virus, they are less likely to infect other people,” he said. 

Notable companies such as Pfizer as well as Merck with partner Ridgeback Biotherapeutics, are also working to develop such antiviral therapies. 


Filed Under: Infectious Disease
Tagged With: main protease, Mpro, Pardes Biosciences, SARS-CoV-2
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE